期刊文献+

染色体17q区拷贝数变异与肝细胞癌总生存的相关性及靶基因的筛选

Association of chromosome 17q copy number variation with overall survival of patients with hepatocellular carcinoma and screening of potential target genes
原文传递
导出
摘要 目的探讨染色体17q拷贝数变异(copynumbervariation,CNV)与肝细胞癌(hepatocellularcarcinoma,HCC)术后总生存(overallsurvival,OS)的相关性以及预后相关CNV内的潜在靶基因。方法纳入HCC手术患者174例,其中66例有完整术后OS随访资料。应用AgilentHu-244A微阵列比较基因组杂交和AffymetrixU133Plus2.0表达芯片分别检测染色体17qCNV和基因表达。结果17q25.1—25.3增益与0S显著相关(P一0.00002)。多因素Cox回归分析显示,17q25.1-25.3增益是0S的独立不良预后因素(HR:3.17,95%CI:1.39~7。26,P=0。006)。基因CNV与mRNA表达的联合分析显示,SLC9A3R1、GRB2、TK1等18个基因mRNA表达水平在基因增益HCC中显著高于基因无增益HCC(FDR-q〈0.05,P〈0.01)及癌旁肝组织(P〈0.01)。结论17q25.1.25.3增益与HCC不良预后有关,可作为HCC的一个预后预测因子。SLC9A3R1、GRB2、TK1基因可能是17q25.1-25.3增益的潜在靶基因。 Objective To assess the association of copy number variations (CNVs) in chromosome 17q with the overall survival(OS) of patients with hepatocellular carcinoma(HCC), and to screen for target genes contained in the OS-related CNVs. Methods A total of 174 HCC cases were enrolled. For 66 patients, the follow-up data was available. High-resolution Agilent Hu-244A array comparative genomic hybridization (aCGH) and Affymetrix U133 Plus 2.0 expression arrays were used to detect CNVs and gene expression of genes from the 17q region, respectively. The association of CNVs and OS was assessed with Log-rank test, Kaplan-Meier survival analysis, and Cox proportional hazards models. The gene expression in HCCs with 17q gain, HCCs without, and non-tumor liver tissues were compared with a Mann-Whitney U test. Results Llnivariate association analysis showed that copy number gain in 17q25. 1-25. 3 was significantly associated with reduced OS (Log-rank test, P=0. 000 02), and HCC cases with 17q25.1-25.3 gain had a 4.76-fold (95%Ch 2.31-9.81) increased hazard ratio (HR) for death from HCC, as compared to those without the gain. Multivariate Cox proportional hazards regression model revealed 17q25.1-25.3 gain to be an independent prognostic marker for poor OS (HR=3.17, 95%CI: 1.39-7.26, P=0. 006). The expression levels of 18 genes in 17q25. 1-25. 3 including SLC9A3R1, GRB2, and TK1 were significantly increased in HCCs with gain than in those without (all P〈0.01) and non-tumor liver tissues (all P〈0.01). Conclusion The association of 17q25. 1-25. 3 gain with reduced OS has indicated that it is a prognostic marker for poor patient survival in HCC, for which SLC9A3R1, GRB2, and TK1 are candidate genes.
出处 《中华医学遗传学杂志》 CAS CSCD 北大核心 2015年第5期615-619,共5页 Chinese Journal of Medical Genetics
基金 国家自然科学基金(30470791) 南京军区医学科技创新基金(08MA023) 宁波自然科学基金(2009A610126)
关键词 肝细胞癌 预后 分子标志 拷贝数变异 基因表达 Hepatocellular carcinoma Prognosis Molecular marker Copy number variationGene expression
  • 相关文献

参考文献3

二级参考文献72

  • 1Sharad Khare,Qiong Zhang,Jamal A Ibdah.Epigenetics of hepatocellular carcinoma:Role of microRNA[J].World Journal of Gastroenterology,2013,19(33):5439-5445. 被引量:12
  • 2钱卫平,谭跃球,谢慧玫,宋丹,关新元,卢光琇.家族性染色体复杂重排的分子细胞遗传学研究[J].中华医学遗传学杂志,2005,22(3):302-304. 被引量:4
  • 3Ann-Lii Cheng,Yoon-Koo Kang,Zhendong Chen,Chao-Jung Tsao,Shukui Qin,Jun Suk Kim,Rongcheng Luo,Jifeng Feng,Shenglong Ye,Tsai-Sheng Yang,Jianming Xu,Yan Sun,Houjie Liang,Jiwei Liu,Jiejun Wang,Won Young Tak,Hongming Pan,Karin Burock,Jessie Zou,Dimitris Voliotis,Zhongzhen Guan.Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial[J]. Lancet Oncology . 2009 (1)
  • 4Chian‐FengChen,Shiou‐HweiYeh,Ding‐ShinnChen,Pei‐JerChen,Yuh‐ShanJou.Molecular genetic evidence supporting a novel human hepatocellular carcinoma tumor suppressor locus at 13q12.11[J]. Genes Chromosom. Cancer . 2005 (3)
  • 5Jordi Bruix,Loreto Boix,Margarita Sala,Josep M Llovet.Focus on hepatocellular carcinoma[J]. Cancer Cell . 2004 (3)
  • 6Rosa C.M.Y Liang,Jason C.H Neo,Siaw Ling Lo,Gek San Tan,Teck Keong Seow,Maxey C.M Chung.Proteome database of hepatocellular carcinoma[J]. Journal of Chromatography B . 2002 (1)
  • 7Yasunobu Matsuda,Takafumi Ichida,Jun Matsuzawa,Kazuhito Sugimura,Hitoshi Asakura.p16 INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma[J]. Gastroenterology . 1999 (2)
  • 8Sakari Knuutila,Yan Aalto,Kirsi Autio,Anna-Maria Bj?rkqvist,Wa’el El-Rifai,Samuli Hemmer,Tarja Huhta,Eeva Kettunen,Sonja Kiuru-Kuhlefelt,Marcelo L. Larramendy,Tamara Lushnikova,Outi Monni,Heini Pere,Johanna Tapper,Maija Tarkkanen,Asta Varis,Veli-Matti Wasenius,Maija Wolf,Ying Zhu.DNA Copy Number Losses in Human Neoplasms[J]. The American Journal of Pathology . 1999 (3)
  • 9CHEN C F,HSU E C,LIN K T, et al.Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma. Hepatology . 2010
  • 10Benowitz Steve.Liver cancer biomarkers struggling to succeed. Journal of the National Cancer Institute . 2007

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部